Company intelligence / Profile preview

Metastatix

Atlanta, Georgia, United Statescancer.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Metastatix was a clinical-stage biopharmaceutical company developing small molecule inhibitors targeting the CXCR4 chemokine receptor, with the aim to prevent cancer metastasis. The lead program reached early clinical development but there are no recent reports of ongoing trials or results. The company appears to have ceased operations and has not reported new data in several years.

No current clinical results available.

Therapeutic areas: OncologyInfectious Diseases
Modalities: small molecules (historically focused on small molecule inhibitors)
Industry: Biotech

Drug pipeline

1 asset

endoxifen

Phase 2

Indications: Metastatic breast cancer, Breast cancer prevention, Neoadjuvant breast cancer

Beyond the preview

Go deeper on Metastatix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metastatix.

Explore the full profile